The quest for ligands and binding partners of atypical cadherin FAT1
| Autor: | Subrata Sinha, Yakhlesh Gupta, Khushboo Irshad, Manvi Arora, Kunzang Chosdol, Nargis Malik |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
GPI
glycosylphosphatidylinositol 0301 basic medicine Cancer Research Glypican GAG glycosaminoglycan Biology Ab antibody 03 medical and health sciences 0302 clinical medicine Fat1 TM transmembrane domain Extracellular medicine Spotlight GPC3 glypican-3 RC254-282 Cancer EGF epidermal growth factor RTP receptor tyrosine phosphatase CAR-T cells chimeric antigen receptor T cells Ligand Cadherin Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Transmembrane protein TRAB T cell-redirecting antibody Cell biology 030104 developmental biology Oncology 030220 oncology & carcinogenesis Function (biology) FAT1 |
| Zdroj: | Translational Oncology, Vol 14, Iss 7, Pp 101097-(2021) Translational Oncology |
| ISSN: | 1936-5233 |
| Popis: | A recent study in Scientific Reports identified glypican-3 (GPC3) as a novel extracellular interacting protein for FAT1 in hepato-cellular carcinoma (HCC) cells. FAT1 is a large transmembrane atypical cadherin with limited knowledge existing about its binding partners. While in Drosophila, dachsous (ds), another transmembrane member of the cadherin superfamily, is known to function as FAT1 ligand, no ligand is known in mammals so far. The revelation of GPC3 as a potential binding partner of FAT1 extracellular domain unfolds an opportunity to study potential triggers of FAT1 signaling in cancers. Available inhibitors of GPC3 in various phases of clinical trials also present an attractive option to curb GPC3-FAT1 signaling in tumors that overexpress these proteins. Graphical abstract Image, graphical abstract |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|